Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
‘More should be done’: UN pushes Syrian regime on justice for Druze, Alawites and minority groups- 6 Agreeable Earphones To Wear
- What's Your #1 Pizza Beating Mix?
- Unsold Rams May Be Less expensive Than You Suspect
- Figure out How to Modify Your Pre-assembled Home for Greatest Solace and Stylish Allure
- Let them eat (Taylor Swift) cake: The baker turning A-listers into life-size desserts
- 6 Popular Ladies' Aromas On the planet
- The Response to Independence from the rat race: Methodologies for Creating Financial momentum
- Why do people get headaches and migraines? A child neurologist explains the science of head pain and how to treat it
